CA
BMY.RT

Calton & Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Calton & Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,122
Closed -$36K – 367
2020
Q2 		$36K Buy
+10,122
New +$36.5K 0.01% 329

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Calton & Associates's BMY.RT Position: Q3 2020 in Review

Calton & Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 10,122 shares — an estimated $36K sold.

Calton & Associates first reported a position in BMY.RT in Q2 2020 and held it in 1 quarter. The position peaked at $36K in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Calton & Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Calton & Associates sold 10,122 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $36K.
  • Calton & Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 1 quarter.
  • Calton & Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $36K in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Calton & Associates's 13F filing for Q3 2020, filed 30 Oct 2020.